Skip to main content
Clinical Trials/NL-OMON39206
NL-OMON39206
Completed
Not Applicable

Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) - A Safety Study - Targeted Lung Denervation in COPD

Holaira, Inc. (IPS)0 sites11 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
chronic bronchitis
Sponsor
Holaira, Inc. (IPS)
Enrollment
11
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Holaira, Inc. (IPS)

Eligibility Criteria

Inclusion Criteria

  • FEV1 30% \- 60% of predicted
  • FEV1/FVC \<70%
  • Positive change in FEV1 of greater than 15% following administration of ipratropium
  • Non\-smoking for a minimum of 6 months and a minimum of 10 packyears of smoking

Exclusion Criteria

  • Prior lung transplant, LVRS, median sternotomy, bullectomy or lobectomy
  • Presence of a pacemaker, internal defibrillator or other implantable electronic devices

Outcomes

Primary Outcomes

Not specified

Similar Trials